Clinical trial
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of…
NCT00038194 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038194 |
|---|---|
| Title | Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer |
| Official title | Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | imatinib mesylate, docetaxel |
| Enrollment | 28 |
| Start date | Oct 1, 2001 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | May 30, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: